Palatin net loss narrows to $8.38 million in FY26; revenue turns to $13.19 million
PTN•Palatin reported an $8.38 million net loss for FY26, down from $17.31 million, and revenue of $13.19 million, compared with none a year earlier. Cash rose to $7.49 million, and the company flagged a need for additional funding.
1. FY26 results
Palatin reported a net loss of $8.38 million for FY26, compared with $17.31 million a year earlier. Loss per share improved to $2.96 from $32.15. Revenue was $13.19 million, including $9.4 million tied to Boehringer Ingelheim, versus no revenue in the prior fiscal year.
2. Cash and development plans
Cash and cash equivalents rose to $7.49 million from $2.56 million at June 30, 2025, and Palatin flagged a need for additional funding. The company targets Phase 1 SAD/MAD testing of a once-weekly injectable MC4R peptide in the first half of 2027, with initial data targeted for the second half of 2027.
